Clinical Trial Update: A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer [Phase 3]

View source ↗

Summary

This is a Phase 3 clinical trial update for abemaciclib in combination with fulvestrant in hormone receptor-positive, HER2-negative breast cancer, with results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Faslodex (fulvestrant) (fulvestrant)
• Verzenio (abemaciclib) (abemaciclib)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Breast Neoplasms | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2018-03-13